Astellas Submits Pediatric Data To U.S. FDA For Flomax Exclusivity; Announces JV With Maxygen
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas Pharma July 1 said its U.S. licensee for Flomax (tamsulosin), Boehringer Ingelheim Pharmaceuticals submitted data to U.S. FDA from a study on pediatric patients with neurogenic bladders - apparently to fend off generics offerings when the drug's patent protection expires later this year